Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST-trial
NCT05263674Phase 3Recruiting
- Sponsor
- University of Southern Denmark
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of propofol in status epilepticus (SE) (2 arms), sponsored by University of Southern Denmark. Primary endpoint: Proportion of patients with continued NCSE on EEG after 24 h. Started Feb 2022; status: recruiting.
02
Drugs
propofol
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT05263674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263674.